HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.

AbstractPURPOSE:
To assess the efficacy and the toxicity of a new combination of epirubicin, cyclophosphamide and paclitaxel as neoadjuvant chemotherapy for breast cancer.
METHODS:
Patients with stage II and III breast cancer received 3-4 cycles of epirubicin 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) on day 1, and paclitaxel at a dose of 100 mg on days 1, 8, 15 and 22 on a 28-day cycle.
RESULTS:
Forty-nine patients were enrolled in the study. Stage II was present in 16 patients (32.7%) and stage III in 33 patients (67.3%). Relevant toxicities were nausea/vomiting grades III-IV in 6 patients (12.2%) and neutropenia grade III-IV in 33 patients (67.3%). The overall clinical response rate was 83.7%. Partial response was observed in 25 patients (51%), complete response in 16 patients (32.7%), stable disease in 7 patients (14.3%) and progression in 1 patient. Thirty-three non-inflammatory breast cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). Pathological complete response was found in 5 patients (15.1%).
CONCLUSIONS:
The combination of epirubicin, cyclophosphamide and weekly paclitaxel as given in this study is safe and shows good activity in the neoadjuvant setting of stage II and III breast cancer patients.
AuthorsDavid Aguiar Bujanda, Uriel Bohn Sarmiento, Miguel Angel Cabrera Suárez, Marta Pavcovich Ruiz, Miguel Angel Limeres González, José Aguiar Morales
JournalJournal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 132 Issue 5 Pg. 332-8 (May 2006) ISSN: 0171-5216 [Print] Germany
PMID16435143 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Epirubicin
  • Cyclophosphamide
  • Paclitaxel
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy, pathology, surgery)
  • Carcinoma (drug therapy, pathology, surgery)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Epirubicin (administration & dosage, adverse effects)
  • Female
  • Humans
  • Infusions, Intravenous
  • Mastectomy, Segmental
  • Middle Aged
  • Neoadjuvant Therapy
  • Paclitaxel (administration & dosage, adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: